

# INDEX

Volume Nine January through December 1975

## DRUG INTELLIGENCE AND CLINICAL PHARMACY

January	Pages 1 - 60
February	Pages 61 - 116
March	Pages 117 - 172
April	Pages 173 - 228
May	Pages 229 - 284
June	Pages 285 - 340

July	Pages 341 - 396
August	Pages 397 - 468
September	Pages 469 - 532
October	Pages 533 - 580
November	Pages 581 - 628
December	Pages 629 - 684

### A

Acidosis, phenformin-induced, 236  
**Actinomycin D**, malignant melanoma, pharmacokinetics (ab) 579  
**Addiction**, treatment, 638  
**β-Adrenergic Blockade**, in essential hypertension (ab) 335  
**Adriamycin IV**, alopecia (ab) 113; stomatitis (ab) 113; vulvitis (ab) 113  
**Adverse Drug Reactions**, 648  
 adriamycin IV, melanotic reaction (ab) 113; stomatitis (ab) 113; vulvitis (ab) 113  
 alkylating agents, myeloma and leukemia (ab) 214  
 alprenolol, reduction of deaths (ab) 58  
 aminophylline, asthma (ab) 57  
 analgesic abuse, renal disease (ab) 331  
 antianxiety drugs, 26  
 antibiotics, pseudomembranous colitis (ab) 278  
 anticoagulants, hemorrhage-breast necrosis (ab) 392  
 anticonvulsant therapy, osteomalacia (ab) 624; rickets (ab) 669  
 antineoplastic agents, 126  
 antipsychotic drugs, 536  
 aspirin, angioedema (ab) 464; urticaria (ab) 464; effects on fetus (ab) 393; renal disease (ab) 331  
 atropine, myocardial infarctions (ab) 393  
 azathioprine, chromosome abnormalities (ab) 393  
**Bendatrin®** (ab) 113  
**Bendectin®**, fatal overdose (ab) 528  
**benztropine**, fatal paralytic ileus (ab) 465  
 bromide intoxication, fatal central nervous system depression (ab) 465  
 busulfan, endocardial fibrosis (ab) 215  
 caffeine, anxiety neurosis (ab) 331  
 cephalothin, nephrotoxicity (ab) 624  
 chlordiazepoxide, death (ab) 393; malformations (ab) 393  
 chloroquine poisoning, death (ab) 392; fatality in children (ab) 465  
 chlorpromazine (ab) 114  
 cigarette smoking, effects on fetus (ab) 393  
 clindamycin, pseudomembranous colitis (ab) 278  
 clinical pharmacy case studies, 190  
 clobetasol, Cushing's syndrome (ab) 577; ointment, generalized pustular psoriasis (ab) 528; pituitary-adrenal suppression (ab) 577  
 codeine, renal disease (ab) 331  
 corticosteroid therapy (ab) 331  
 cost, 257  
 cyclophosphamide, chromosome abnormalities (ab) 333  
 cytotoxic chemotherapy, long-term complications (ab) 164  
 dexamethasone nasal spray, abuse of (ab) 163  
 diazepam, asthma (ab) 278  
**Dilantin®**, intravascular coagulation, purpura fulminans (ab) 669  
 diphenhydantoin, choreoathetosis (ab) 58; fetal abnormalities (ab) 333  
 disulfiram, organic brain syndrome (ab) 163  
 drug induced hemolytic anemia (ab) 277; lupus-like syndrome (ab) 278  
 drug withdrawal in newborns (ab) 214  
 editorial, 321, 382  
 ferrous succinate (ab) 112  
 gold chrysotherapy, in Sjogren's Syndrome (ab) 164  
 gold injections, thrombocytopenia (ab) 278  
 haloperidol, dyskinesia (ab) 163; limb malformations (ab) 164; lithium carbonate, brain damage (ab) 58  
 halothane, postoperative effect on liver enzymes (ab) 392; SGOT level increase (ab) 464  
 heparin, thrombocytopenia (ab) 333  
 heroin, withdrawal in neonates (ab) 528  
 hexachlorophene, neurotoxicity (ab) 332  
 hydantoin, fetal syndrome (ab) 669

hydrocortisone, anaphylactic reaction (ab) 331  
**Inderal** (letter) 455  
 iodide, intoxication (ab) 113  
 iodine, goiter (ab) 112; hyperthyroidism (ab) 112  
 lithium, 17; flu-like syndrome (ab) 332; heart failure (ab) 163; multifocal myoclonus (ab) 332  
 lithium carbonate, haloperidol, brain damage (ab) 58  
**Lomotil®** overdose (ab) 114  
 lupus-like syndrome (ab) 278  
 mandrax overdose, peripheral neuropathy (ab) 577  
 melphalan, myelomonocytic leukemia (ab) 214  
 meprobamate, death (ab) 393; malformations (ab) 393  
 methadone withdrawal, fetal stress (ab) 465; in neonates (ab) 528  
 methyldopa, hemolytic anemia (ab) 277  
 methylprednisolone, anaphylactic reaction (ab) 331  
 monitoring, 80  
 nitrofurantoin, hepatic injury (ab) 278  
 novobiocin-tetracycline, pseudomembranous colitis (ab) 278  
 oral contraceptives, breast cancer (ab) 464; intracranial venous thrombosis (ab) 163; myocardial infarction (ab) 527, 528; stroke (ab) 393  
 penicillamine, Goodpasture's Syndrome (ab) 464  
 penicillin, hemolytic anemia (ab) 277, 577; pseudomembranous colitis (ab) 278  
 pharmacist's role, 12  
 phenacetin, renal disease (ab) 331  
 phenformin, lactic acidosis (ab) 236  
 phenothiazines, fatal paralytic ileus (ab) 465  
 potassium iodine, cardiac irritability (ab) 113  
 propoxyphene overdose (ab) 113  
 prothiouracil, liver disease (ab) 215  
 prostaglandin F<sub>2</sub> alpha, pregnancy termination (ab) 331  
 quinidine, hemolytic anemia (ab) 277  
 quinolonic acid, percutaneous absorption (ab) 624  
 sodium warfarin, ecchymosis (ab) 392  
 steroids, peliosis hepatis (ab) 114  
 succinylcholine, hypotension (ab) 214  
 sulfamethoxazole, allergic reaction, 660  
 tannic acid, hepatotoxicity (ab) 115  
 thiethixene, hypotremia (ab) 279  
 tolbutamide, inotropic effects (ab) 214  
 trimethadione, fetal syndrome (ab) 669  
 vincristine, increased secretion of ADH (ab) 394  
 vinyl-chloride, liver disease (ab) 278  
 vitamin E, coagulopathy (ab) 58  
 warfarin, hemorrhage-breast necrosis (ab) 392  
**Aikman, Jane** (author) book review, 389  
**Alcohol**, drug abuse, 300, 370; drug interactions (ab) 670; interaction with amitriptyline (ab) 527, with chlordiazepoxide (ab) 623, with chlorimipramine (ab) 527, with diazepam (ab) 623, with doxepin (ab) 527, with nortriptyline (ab) 527, with placebo (ab) 527, with thioridazine (ab) 623  
**Alexander, Michael M.** (author) abstracts, 57, 112, 113, 114, 162, 163, 164, 212, 214, 215, 217, 277, 278, 279, 280, 331, 332, 334, 335, 394, 466, 624, 671; letter concerning error in digoxin dose in December 1974 article, 154  
**Alkytating Agents**, adverse reaction (ab) 214  
**Allen, Marcia D.** (co-author) Role of Nurse and Pharmacist Monitors in the Boston Collaborative Drug Surveillance Program, 648  
**Allerest**, interaction with amphetamine (ab) 57  
**Allergic Reactions**, tartrazine, 198  
 alprenolol, reduction of deaths (ab) 58  
**Amantadine**, interaction with ketamine anesthesia (ab) 213

**American Institute of the History of Pharmacy**, assistance to Bicentennial speakers (letter) 570  
**American Pharmaceutical Association**, roles, 406  
**American Society of Hospital Pharmacists**, new goals for (letter) 101; roles, 406  
**Aminophylline**, asthma (ab) 57  
**Aminopyrine** Metabolism, assessment of (ab) 279  
**Amitriptyline**, interaction with alcohol (ab) 527  
**Amphetamine**, interaction with Allerest (ab) 57; with Contac (ab) 57  
**Ampicillin**, in haemophilus influenza meningitis (ab) 394  
**Analgesics**, nephropathy (ab) 331  
**Angaran, David M.** (author) My Son, the Clinical Pharmacist, 298; A White Coat, Name Tag and Beeper, 566; (ed) The Experts, 204  
**Analgesic Abuse**, renal disease (ab) 331  
**Antacids**, duodenal ulcers (letter), 54  
**Antianxiety Drugs**, interactions, 28  
**Antibiotics**, batch certification and bioequivalence (ab) 578; penetration into sputum (ab) 164; prophylactic, vaginal hysterectomy (ab) 165; pseudomembranous colitis (ab) 278; utilization (letter) 155  
**Anticoagulants**, hemorrhage-breast necrosis (ab) 392  
**Anticonvulsant Therapy**, adverse reaction (ab) 689; osteomalacia (ab) 624  
**Antineoplastic Agents**, and fever, 126  
**Antipsychotic Drugs**, interactions, 536  
**Area Below Plasma Concentration Time-Curves**, an equation for (ab) 625  
**Arkwright, Thomas W.** (author) abstracts, 214, 394  
**Aspirin**, adverse effects on fetus (ab) 393; angioedema (ab) 464; urticaria (ab) 464; interaction with heparin (ab) 162; intoxication, 350; myocardial infarction (ab) 115; renal disease (ab) 331; See also Salicylates  
**Atropine**, myocardial infarctions (ab) 393; PGF<sub>2α</sub>-induced bronchoconstriction (ab) 529  
**Audiovisual Aids**, use in patient counseling, 485  
**Azathioprine**, chromosome abnormalities (ab) 393; comparison in myeloma (ab) 216  
**B**  
**Bacterial Meningitis**, case study, 242; comment and author response (letters) 457  
**Bacteroides Infections**, metronidazole in (ab) 279  
**Barger, Robert C.** (author) letter concerning adsorption of insulin in protein solutions, 664  
**Barto, Mary H.** (author) Dantrolene Sodium Evaluation, 42  
**Baughner, Donald R.** (author) Community Pharmacy Practice in the Year 2000, 420  
**Belcastro, P. F.** (author) letter concerning clinical and traditional pharmacy practice, 568  
**Benadryl®**, withdrawal in newborn (ab) 113  
**Bendectin®**, fatal overdose (ab) 528  
**Bender, Kenneth J.** (author) Salicylate Intoxication, 350  
**Benzodiazepines**, interactions, 26  
**Benzotropine**, and phenothiazines, fatal paralytic ileus (ab) 465  
**Benzyl Alcohol**, toxicity of (letter) 154  
**Bergman, H. David** (author) Prescribing of Drugs in a Nursing Home, 365  
**Betker, Rita M.** (author) letter concerning editorial about tartrazine, 568  
**Billingsley, Len A.** (author) letter concerning gentamicin overdosage, 618  
**Bioavailability**, evaluating (letter) 55  
**Biopharmaceutics**, 501; of dantrolene, 42; See also Pharmacokinetics  
**Black, Curtis D.** (co-author) Potential Drug Interactions—Fact or Fallacy?, 586  
**Boards of Pharmacy**, roles, 406  
**Bodenndoerfer, Thomas W.** (author) letter concerning pharmacy's quest for professional direction, 206

**Bodner, Benjamin M.** (author) letter concerning antibiotic utilization, 155  
**Bollinger, R. O.** (co-author) Isolation, Propagation, Freeze Preservation and Studies of Drug Sensitivity of *Toxoplasma gondii* in Human Tissue Culture, 264  
**Books Reviewed**  
 Applied Therapeutics for Clinical Pharmacists (L. Y. Young and M. A. Kimble), 460  
 Assessment of the Carcinogenicity and Mutagenicity of Chemicals (WHO Scientific Group), 211  
 The Bioavailability of Drug Products (American Pharmaceutical Association), 572  
 Bioavailability of Drugs: Principles and Problems (WHO Scientific Group), 210  
 The Biological Imperatives: Health, Politics and Human Survival (A. Chase), 104  
 Bugs and Drugs, Volume 3 (J. H. Muholland, et al.), 461  
 Drug Abuse in Industry (J. M. Scher), 574  
 Drug Interactions and Their Mechanisms (I. H. Stockley), 460  
 Drug Therapy of Cancer (G. Brulé, S. J. Eckhardt, T. C. Hall, & A. Winkler), 210  
 Drug Treatment in Intestinal Helmintiases (A. Davis), 104  
 Drugs and Athletic Performance (M. H. Williams), 523  
 Drugs and the Developing Brain (A. Vernadakis and N. Weiner), 522  
 The Etiology of Alcoholism (J. B. Roebuck and R. G. Kessler), 389  
 Index Nominum 1975/76 (Laboratory of the Swiss Pharmaceutical Society in Zurich), 522  
 The National Formulary XIV (National Formulary Board of Trustees), 389  
 Pediatrics - 15 (H. L. Barnett, A. H. Einhorn), 103  
 Pharmaceutical Calculations, 6th ed (M. J. Stoklosa), 105  
 Pharmacodynamics and Patient Care (M. P. Johns), 574  
 Pharmacy, Drugs and Medical Care (M. C. Smith and D. A. Knapp), 461  
 The Physician's Assistant: Today and Tomorrow (A. M. Sadler, B. L. Sadler, A. A. Bliss), 103  
 Plastic Containers for Pharmaceuticals - Testing and Control (J. Cooper), 102  
 Pocket Consult, Antiepilepsy Agents (M. J. Reilly), 572  
 Principles and Techniques of Human Research and Therapeutics - Volume IV, Importance of Experimental Design and Biostatistics (F. G. McMahon), 572  
 Principles of Medicinal Chemistry (W. O. Foye), 212  
 Progress in Medicinal Chemistry, Volume II (G. P. Ellis and G. B. West), 573  
 Psychosocial Pharmacy: The Synthetic Society (F. B. Gable), 104  
 Sterile Dosage Forms: Their Preparation and Clinical Application (S. Turco and R. E. King), 212  
 WHO Expert Committee on Drug Dependence: Nineteenth Report (World Health Organization Technical Report Series), 211  
 WHO Expert Committee on Drug Dependence: Twentieth Report (World Health Organization Technical Report Series), 102  
**Born, Emilie S.** (author) letter concerning clinical pharmacology - clinical pharmacy seminar, 278  
**Bosso, John A.** (author) Bacterial Meningitis, 242; *Pneumocystis Carinii* Pneumonia Treated with Pentamidine, 657; letter replying to comments on Bacterial Meningitis article, 457; (co-editor) Pediatric Clinical Pharmacy Case Studies, 242, 657  
**Bowman, John D.** (author) letter concerning Cost Effectiveness Comparison article, 517  
**Bradberry, J. Chris** (ed) Responsibility of Practice, 383  
**Brand Name and Generic Prescriptions**, consumer price differentials (ab) 222  
**Branson, Joanne B.** (author) book reviews, 104, 105  
 Bromide Intoxication, fetal CNS depression (ab) 465  
**Bryan, Candace K.** (ed) Pharmacy's Private Practitioner, 513  
**B.Sc. and Pharm.D.**, one or two degrees? (letter), 569  
**Bumetanide**, in pulmonary edema (ab) 216  
**Burkhart, Vincent dePaul** (co-author) Technical and Theoretical Aspects of Patient Counseling Using Audio Visual Aids, 485  
**Busulfan**, endocardial fibrosis (ab) 215

**Carbamazepine**, pharmacokinetics (ab) 529  
**Carbenicillin Therapy**, normal and impaired renal function (ab) 579  
**Cardoni, Alex A.** (co-author) A Course in Psychotropic Drug Therapy for First-Year Psychiatry Residents, 318  
**Cargile, Charles M.** (author) Carrying Capacity, Population & the Quality of Life, 38  
**Case Studies**, salicylate intoxication, 350  
**Catheters**, contamination, 76  
**Cefazolin**, kinetics in renal failure and dialysis (ab) 670  
**Cephaloridine**, in bacterial meningitis (ab) 395  
**Cephalothin**, in bacterial meningitis (ab) 395; nephrotoxicity (ab) 624; by venous catheter (ab) 165  
**Chan, Peter W.** (author) letter concerning use of antacid for decubitus ulcers, 54  
**Charcoal**, management of poisoning with (ab) 334  
**Chaussade, J.** (author) letter concerning polyvinyl chloride plastics for IV use, 518  
**Chloral Hydrate**, interaction with furosemide (ab) 466  
**Chlorambucil**, comparison in myeloma (ab) 218  
**Chloramphenicol**, interaction with cyclophosphamide (ab) 624  
**Chlordiazepoxide**, death (ab) 393; interaction with alcohol (ab) 623, with diazepam (ab) 623, with thioridazine (ab) 623; malformations (ab) 393  
**Chlorimipramine**, interaction with alcohol (ab) 527  
**Chlordydine**, dependence (ab) 223  
**Chloroprocaine**, paracervical block with (ab) 280  
**Chloroquine**, intestinal amebiasis (letter) 569  
**Chloroquine Poisoning**, death (ab) 392; fatality in children (ab) 465  
**Chlorpromazine**, adverse reaction (ab) 114; interaction with orphenadrine (ab) 623, with phenobarbital (ab) 623  
**Cholesterol**, plasma, effect of oral contraceptives (ab) 670  
**Chudzik, Gregory M.** (co-editor) Pediatric Clinical Pharmacy Case Studies, 242, 657  
**Cigarette Smoking**, adverse effects on fetus (ab) 393  
**Cirrhosis**, elimination of clindamycin (ab) 466  
**Clindamycin**, elimination in cirrhosis (ab) 466; pseudomembranous colitis (ab) 278; renal impairment (ab) 334; treatment of skin infections (ab) 217  
**Clinical Pharmacology**, clinical pharmacy seminar (letter) 276  
**Clinical Pharmacist's Roles**, 12, 480, 485, 566, 638, 648; drug monitoring, 80; educational, 316; future, 406, 426, 439; pain conditioning, 68; patient education, 601; primary care, 129; satire, 298; letter praising satire, 457  
**Clinical Pharmacy**  
 clinical pharmacology seminar (letter) 276  
 cost justification, 257  
 dilemma of (letter) 54; possible solution (letter) 55  
 education, rise and fall (ed) 97; education, future, 447  
 legal aspects, 124  
 pharmacist-physician coordination, 86  
 and physicians, 129  
 practice, 606; editorial, 321; the experts (ed) 204; hospital rounds (ed) 270; "pharmacists' syndrome" (ed) 151; quest for professional direction (ed) 45; strategy for hard times (ed) 204; and traditional services (ed) 151, (letter) 328  
 practice in year 2000, 406; community, 420; educational needs, 447; impact of computers, 439; impact of technicians, 430; impact of technologists, 434; possible determinants of practice, 426; women, 412, 415  
 principles, 12  
 satire, A White Coat, Name Tag and Beepers, 566  
 residents, state licensure (ed) 97  
 service, 553; patient education (ed) 322; service-who needs it? (ed) 323  
 strategy for hard times (ed) 204  
 vs. Traditional Practice (letters) 329, 568  
**Clinical Pharmacy Case Studies**, adverse drug reactions, 190; bacterial meningitis, 242; peptic ulcer, 86; *Pneumocystis carinii* pneumonia treated with pentamidine, 657  
**Clobetasol**, Cushing's syndrome (ab) 577; ointment, generalized pustular psoriasis (ab) 528; pituitary-adrenal suppression (ab) 577  
**Clonidine Hydrochloride**, A.M.A. evaluation of (ab) 578  
**Cloud, James** (co-author) A Self-instructional Learning Package About Parenteral Hyperalimentation for Students of Nursing, Pharmacy and Medicine, 493  
**Coats, Eugene A.** (author) book review, 573  
**Cocaine**, renal disease (ab) 331  
**Cohen, Monte S.** (author) Tartrazine Revisited, 198; letter, addendum to tartrazine article, 330  
**Communications**, verbal, of community pharmacists (ab) 622  
**Community Pharmacy**, conclusions and recommendations (ab) 632; education and roles (letter) 618; future, 420; pharmacist's professional opportunity (ed) 514; practice in year 2000 (ed) 454; verbal communications of pharmacists (ab) 622  
**Competency of Practitioners**, 426, 591  
**Compliance**, patient (ed) 268  
**Compounding Accuracy**, 591  
**Computers**, future use, 439; patient monitoring (letter) 516  
**Contact, interaction with amphetamine** (ab) 57  
**Contamination**, IV and catheter, 76  
**Continuing Education**, drug therapy course (letter), 276; open university in Tennessee (letter), 101; quiz, 180  
**Cooper, Jack** (author) letter concerning polyvinyl chloride plastics for IV use, 519  
**Corticosteroid Therapy**, anaphylaxis-like reactions (ab) 331  
**Cost Effectiveness Comparisons**, 257; comment and author reply (letters) 517, 518  
**Cost Justification**, clinical pharmacy, 257  
**Courts**, future roles, 426  
**Covinsky, Joel O.** (ed) "Pharmacists' Syndrome," 151  
**Cryptococcosis**, flucytosine, 180  
**Cryptococcosis**, chromosome abnormalities (ab) 333; interaction with chloramphenicol (ab) 624, with sulfaphenazole (ab) 624  
**Cytarabine** (ab) 395  
**Cytotoxic Chemotherapy**, long-term complications (ab) 164

## D

**D-1-T**, investigational drug, 655  
**Dantrolene**, See Dantrolene Sodium  
**Dantrolene Sodium**, evaluation, 42; treatment of spasticity (ab) 334  
**Darvon**, positive results for methadone screening (letter) 515  
**Davis, Larry F.** (author) Drug Evaluation Data, Ibuprofen, 501; letter concerning lidocaine in myocardial infarction, 275  
**Deans**, and professional degrees (ed) 205, (letters) 330, 515  
**Degrees**, B.Sc. and Pharm.D. (letter) 569; professional, and deans (ed) 205, (letters) 330, 515; professional, vs. self-education (letter) 100  
**de Haen, Paul** (author) The Drug Lag - Does it Exist in Europe?, 144; New Products 1973-1974, U.S.A., 504; reply to Bruce Fisher concerning his cards, 664  
**DeLattre, Mary** (author) letter concerning heparin strengths, 387  
**Dencker, Lennart** (author) book review, 522  
**Dexamethasone Nasal Spray**, abuse of (ab) 163  
**Dextroamphetamine**, interaction with Contac (ab) 57; interaction with Allerest (ab) 57  
**Diabetes Mellitus**, nurse practitioner in the management of patients with (ab) 222  
**Diabetic Ketoacidosis**, therapy, 135  
**DIAIDS Rounds**, 190  
**Diazepam**, asthma (ab) 278; interaction with alcohol (ab) 623, with chlordiazepoxide (ab) 623, with thioridazine (ab) 623; placental transfer (ab) 579; thioridazine as an alternate (ab) 335  
**Dick, M. Lawrence** (co-author) A Cost Effectiveness Comparison of a Pharmacist Using Three Methods for Identifying Possible Drug Related Problems, 257; (author) reply to comment on article, 518  
**DICP**, diet and community practitioners (letter) 207  
**Diet**, in ketoacidosis, 135  
**Digitoxin**, metabolism and excretion (ab) 59  
**Digoxin**, error in dose in December 1974 article (letter) 154; intoxication, salivary levels as an indicator (ab) 671; serum levels (letter) 274  
**Dilantin®**, adverse reaction (ab) 669  
**Dilemma of Clinical Pharmacy** (letter) 54; possible solution (letter) 55  
**Diodoquin®**, intestinal amebiasis (letter) 569  
**Diphenhydramine**, overdose, peripheral neuropathy (ab) 577  
**Diphenhydantoin**, choreoathetosis (ab) 58; dosage (letter) 274; fetal abnormalities (ab) 333; pulmonary function loss (ab) 165  
**Diplococcus pneumoniae**, 242  
**Disulfiram**, organic brain syndrome (ab) 163  
**Dopamine**, shock therapy (letters) 456, 665  
**Doxepin**, interaction with alcohol (ab) 527  
**Driperidol**, cardiovascular effects (ab) 217  
**Drug Abuse**, 249; education, untoward effects of (ab) 223; origin and prevention, 300; patient-authorized refills, 489; prevention, 370; traffic accidents, 370; treatment, 638  
**Drug Actions, Interactions and Reactions**, 57, 112, 162, 213, 277, 331, 392, 464, 527, 577, 623, 669  
**Drug Compounding**, accuracy, 591  
**Drug Dependence**, 638; WHO Report, Part I, 249; Part II, approaches to prevention, 300; Part III, conclusions and recommendations, 370

## INDEX

**Drug Dosage**, estrogen (ab) 165; flucytosine, 180  
**Drug Evaluation Data**, Calcitonin-Salmon, 557; Dantrolene Sodium, 42; Ibuprofen, 501; Sodium Nitroprusside, 361  
**Drug History**, 80  
**Drug-Induced Illness**, pharmacist's role, 12; hemolytic anemia (ab) 277; lupus-like syndrome (ab) 278  
**Drug Information**, indexing and abstracting services, 190; techniques, 190  
**Drug Information Centers**, role in formulary revision, 596  
**Drug Interactions**, 536, 588  
 alcohol (ab) 670; amitriptyline (ab) 527; chlordiazepoxide (ab) 623; chlorimipramine (ab) 527; diazepam (ab) 623; doxepin (ab) 527; mirtazapine (ab) 527; placebo (ab) 527; thioridazine (ab) 623  
 Allerest-ampetamine (ab) 57  
 amantadine-ketamine anesthesia (ab) 213  
 amitriptyline-alcohol (ab) 527  
 amphetamine-Allerest (ab) 57; Contac (ab) 57  
 antianxiety drugs, 26  
 antipsychotic drugs, 536  
 aspirin-heparin (ab) 162  
 barbiturates-anticoagulants, 589; griseofulvin, 589  
 benzotropine-phenothiazines (ab) 465  
 calcium gluconate-potassium citrate (ab) 466  
 chloral hydrate-furosemide (ab) 466  
 chloramphenicol-cyclophosphamide (ab) 624; anticoagulants, 589  
 chlordiazepoxide-alcohol (ab) 623; diazepam (ab) 623; thioridazine (ab) 623  
 chlorimipramine-alcohol (ab) 527  
 chlorpromazine-orphenadrine (ab) 623; phenobarbital (ab) 623  
 cholesterol, plasma-oral contraceptives (ab) 670  
 cholestryamine-thyroid, 587  
 clindamycin, cirrhosis (ab) 466  
 CNS drug interactions, antipsychotics, 536  
 Contac-ampetamine (ab) 57  
 cyclophosphamide-chloramphenicol (ab) 624; sulfaphenazole (ab) 624  
 diazepam-alcohol (ab) 623; chlordiazepoxide (ab) 623; thioridazine (ab) 623  
 doxepin-alcohol (ab) 527  
 editorial, 269  
 ephedrine-theophylline (ab) 527  
 ethacrynic acid-warfarin (ab) 213  
 furosemide-chloral hydrate (ab) 466  
 gallamine-morphine (ab) 277; nitrous oxide (ab) 277; oxygen anesthesia (ab) 277;  
 tubocurarine (ab) 277  
 heparin-aspirin (ab) 162  
 hepatic drug metabolizing enzymes-phenobarbital (ab) 623  
 hydroxyzine-theophylline (ab) 527  
 hyperbaric oxygen and drugs (letter) 276  
 ketamine anesthesia-amantadine (ab) 213  
 laboratory tests, 26  
 levodopa-papaverine (ab) 214  
 methylidopa-thiazide (ab) 577  
 minoxidil-propranolol (ab) 162  
 morphine-gallamine (ab) 277; pancuronium (ab) 277; propranolol (ab) 277  
 nitrous oxide-gallamine (ab) 277; pancuronium (ab) 277  
 nortriptyline-alcohol (ab) 527  
 oral contraceptives-plasma vitamins, cholesterol and triglycerides (ab) 670  
 orphenadrine-chlorpromazine (ab) 623  
 oxygen anesthesia-gallamine (ab) 277;  
 pancuronium (ab) 277  
 pancuronium-morphine (ab) 277; nitrous oxide (ab) 277; oxygen anesthesia (ab) 277;  
 tubocurarine (ab) 277  
 papaverine-levodopa (ab) 214  
 penicillin-neomycin, 587  
 phenformin-vitamin B<sub>12</sub> (ab) 162  
 phenobarbital-chlorpromazine (ab) 623; hepatic drug metabolizing enzymes (ab) 623; vitamin D (ab) 670  
 phenothiazines-benzotropine (ab) 465; and antacids, 589  
 placebo-alcohol (ab) 527  
 potassium citrate-calcium gluconate (ab) 466  
 potential drug interactions - fact or fallacy, 586  
 propranolol-minoxidil (ab) 162; morphine (ab) 277  
 pseudoephedrine-triprolidine (ab) 213  
 psychotherapeutic drugs, 536  
 rifampin-warfarin (ab) 466  
 spironolactone-urinary pH (ab) 57  
 sulfaphenazole-cyclophosphamide (ab) 624  
 theophylline-ephedrine (ab) 527; hydroxyzine (ab) 527  
 thiazide-methyldopa (ab) 577  
 thioridazine-alcohol (ab) 623; chlordiazepoxide (ab) 623; diazepam (ab) 623  
 triglycerides, plasma-oral contraceptives (ab) 670  
 triprolidine-pseudoephedrine (ab) 213  
 tubocurarine-gallamine (ab) 277; pancuronium (ab) 277

urinary pH-spironolactone (ab) 57  
 vitamin B<sub>12</sub>-phenformin (ab) 162; malabsorption (ab) 466  
 vitamin D-phenobarbital (ab) 670  
 vitamins, plasma-oral contraceptives (ab) 670  
 warfarin-ethacrynic acid (ab) 213; rifampin (ab) 466  
**Drug Lag**, 144  
**Drug Marketing**, lag in, 144  
**Drug Monitoring**, See Drug Utilization  
**Drug Products**, tartazine-containing, 198  
**Drug Sensitivity**, of *Toxoplasma gondii*, 264  
**Drug Services**, contrasting approaches to (ab) 223  
**Drug Surveillance**, See Drug Utilization  
**Drug Therapy**, 606; arthritis, 501; chronic spasticity, 42; clinical pharmacist's roles, 12, 406; continuing education course (letter) 276; cryptococcal meningitis, 180; detoxification, poly drug abuse, 638; diabetic ketoacidosis, 135; effectiveness, 292; new drugs 1973/1974, 504; of pain, 68; problems in hospitals, 80; psychotropic, 316; rational, 480; salicylate intoxication, 350  
**Drug Use Control**, See Drug Utilization  
**Drug Utilization**, appropriate, 292; case study, 86; clinical pharmacist's role, 80; clinical pharmacy residencies, 606; computers, 439; nursing homes, 365; overprescribing, 480; PSRS, 553, 648  
**Durham-Humphrey Amendment**, 489

## E

### Editorial Advisory Board (ed), 45

**Editorials**  
 David M. Angaran, The Experts, 204  
 J. Chris Bradberry, Responsibility of Practice, 383  
 Candace K. Bryan, Pharmacy's Private Practitioner, 513  
 Joel O. Covinsky, Pharmacists' Syndrome, 151  
 Donald E. Francke, The Community Pharmacist's Professional Opportunity, 514; Editorial Advisory Board, 45; The Five-Year Pharm.D., 384; Guidelines for Pharm.D. Programs, 617; Pharmacy in the Year 2000, 454; Population and the Quality of Life, 46; Professional Degrees and Deans, 205; Salute to Women Pharmacists, 663; Temporary State Licensure for Pharmacy Residents, 97  
 John T. Frank, Pharmacy's Quest for Professional Direction, 45  
 Philip D. Hansten, Adverse Drug Reactions - Do We Really Know?, 321  
 Leslie Hendeles, Wandering from Bed to Bed, 270  
 Hugh N. Lunan, Drug-Drug Interactions, 289; New Developments in Pharmacy - How Does the Institution Meet This Need?, 453  
 Don C. McLeod, Strategy for Clinical Pharmacy in Hard Times, 204; The Dilemma in Pharmacy Residency Training, 382  
 Paul G. Pierepaoli, The Rise and Fall of Clinical Pharmacy Education, 97  
 Robert G. Pietrusko, Clinical Pharmacy Service - Who Needs It?, 323  
 L. Kent Porter, The Literature and the Pharmacist, 513  
 Randall A. Prince, The Need for Pharmacokinetic Data in Diseased Individuals, 272  
 Robert P. Rapp, Patient Oriented Pharmacy Practice - Does it Include Traditional Services?, 151  
 Thomas P. Reinders, Patient Education - A Clinical Pharmacy Service, 322  
 John A. Romankiewicz, Spanning the Gap - Clinical Research, 324  
 Dorothy L. Smith, Why Should Patients Comply with Medication Instructions?, 268  
 Ronald B. Stewart, The Fatal Drug-Reaction Debate, 382; What the Pharmacist Needs to Know, 664  
 Diane E. Tobias, Round and Round, 321  
 Harvey A. K. Whitney, Jr., Educating the Public about Drugs, 571; Education and Utilization of Pharmacy Supportive Personnel, 452; The Five-Year Pharm.D., 384  
**Editor's Reply** to comments on editorial (letter) 620  
**Education**  
 clinical pharmacy, rise and fall of (ed) 97  
 continuing, drug therapy course (letter) 276; open university in Tennessee (letter) 101; quiz, 180  
 drug abuse, untoward effects of (ab) 223  
 educating the public about drugs (ed) 571  
 future, 406; clinical, accreditation, 447  
 open university in Tennessee (letter) 101  
 patient, 485, 601; a clinical pharmacy service (ed) 322; compliance with medication instructions (ed) 268  
 "pharmacists' syndrome" (ed) 151  
 pharmacy supportive personnel (ed) 452

**Pharm.D. Programs**, five-year (ed) 384; letter, 619; guidelines for (ed) 617; list of (letter) 207  
 physicians and nurses, 80  
 professional degrees, and deans (ed) 205; vs. self-education (letter) 100  
 professional literature (ed) 513  
 residency training (ed) 382; 606  
 role of clinical pharmacist, 316  
 residents, teaching and service responsibilities, 606  
 What the pharmacist needs to know (ed) 664  
 Elliott, Roger K. (author) letter concerning new goals for ASHP, 101  
**Emetine**, intestinal amebiasis (letter) 569  
**Environmental Contamination**, population (ed) 46  
**Ephedrine**, interaction with theophylline (ab) 527  
**Epidemiology**, 648  
**Errors in Compounding**, 591  
 Eshelman, Fred N. (author) book review, 574  
**Estrogen**, dosage in post-menopausal osteoporosis (ab) 165  
**Ethacrynic Acid**, interaction with warfarin (ab) 213  
**Evans**, William E. (co-author) Acute Renal Failure in a Multisystem Allergic Reaction to Sulfamethoxazole, 860  
**Evens**, Ronald P. (author) letter concerning toxicity of intravenous benzyl alcohol, 154  
**Excretion**, of salicylates, 350

## F

### Faculty, women, 412

**Family Planning**, 36  
**Family Practitioner Article**, omission of acknowledgement (letter) 54  
 Farr, Glen E. (author) letter concerning open university in Tennessee, 101  
**Federal Food, Drug and Cosmetic Act**, 489  
**Fentanyl**, cardiovascular effects of (ab) 217  
**Ferrous Succinate**, adverse drug reaction (ab) 112  
**Female Control**, and the quality of human life (ab) 222  
**Fetus**, *Toxoplasma gondii*, 264  
**Fever**, from antineoplastic agents, 126  
**Filters**, and phlebitis, 76  
 Fink, Joseph L., III (author) letter concerning editorial on professional degrees and deans, 515  
 Fink, Andrew (co-author) letter concerning clinical pharmacy practice, 55  
 Fisher, Bruce (author) humorous poem about Paul de Haen's cards, 567  
**Five-Year Pharm.D. Programs** (ed) 384; letter, 619; editorial response, 620  
**Floctafenine**, comparison with pentazocine (ab) 529  
**Flucytosine**, pharmacokinetics, 180; See also Fluorocytosine  
**Fluids**, in salicylate intoxication, 350  
**5-Fluorocytosine**, and disseminated candidiasis (ab) 115; See also Flucytosine  
 Fong, Gary R. (author) The Role of the Pharmacist in an Operant Conditioning Program for Chronic Pain Patients, 68  
**Food and Drug Administration**, new drugs, 504  
**Formulary**, hospital, revision, 596  
**Formulations**, for pain medication, 68  
 Francke, Donald E. (editors) The Community Pharmacist's Professional Opportunity, 514; Editorial Advisory Board, 45; The Five-Year Pharm.D., 384; Pharmacy in the Year 2000, 454; Population and the Quality of Life, 46; Professional Degrees and Deans, 205; Salute to Women Pharmacists, 663; Temporary State Licensure for Pharmacy Residents, 97; (author) letter responding to comments on editorial, 620  
 Frank, John T. (ed) Pharmacy's Quest for Professional Direction, 45  
**Furosemide**, interaction with chloral hydrate (ab) 466

## G

**Gallamine**, interaction with morphine (ab) 277, with nitrous oxide (ab) 277, with oxygen anesthesia (ab) 277, with tubocurarine (ab) 277  
 Gallelli, Joseph F. (co-author) Investigational Drug Information, 655  
 Gardner, Sue (co-author) The Impact of the Pharmacy Technologist Upon Pharmacy Practice in the Year 2000, 434  
 Garrison, Thomas J. (author) letter concerning editorial on five-year Pharm.D., 619  
 Gatlin, Larry A. (co-author) Investigational Drug Information, 655  
 Gelperin, Abraham (author) A Supreme Court Decision Will Require Clinical Pharmacy, 124  
**Generic and Brand Name Prescriptions**, consumer price differentials (ab) 222  
**Genetic Variations**, in drug response (ab) 279  
**Gentamicin**, blood levels, guide to nephrotoxicity (ab) 671; dose regimen of (ab) 394; heparin, 586

peritoneal dialysis solutions (letter) 388; overdose (letter) 618; reduction in heparin activity (letters) 568

**Gerbracht, Louise** (author) letter concerning heparin and gentamicin in peritoneal dialysis solutions, 388; (co-author) letter concerning reduction in heparin activity by gentamicin, 568

**Geriatric Patients**, prescribing for, 365

**Giorgianni, Salvatore J.** (author) letter concerning dopamine for shock therapy, 665

**Gissendanner, Clarence E.** (author) book reviews, 212

**Giusti, Donald L.** (co-author) *The Pharmacokinetics of Flucytosine in Cryptococcal Meningitis*, 180

**Glues**, fast-drying, hazards of (letter) 515

**Gold Chrysotherapy**, in Sjogren's Syndrome (ab) 184

**Gold Injections**, thrombocytopenia (ab) 278

**Gong, William C.** (co-author) *Phenformin Induced Lactic Acidosis: A Case Report and Review of the Literature*, 236

**Government**, future roles, 426

**Greenblatt, David J.** (co-author) *Role of the Nurse and Pharmacist Monitors in the Boston Collaborative Drug Surveillance Program*, 648

**Greene, Russell J.** (author) *Clinical Pharmaceutical Aspects of Lithium Therapy*, 17

**Griffin, Gerald** (author) letter about clinical pharmacy practice, 54

**Grimes, George J.** (co-author) *Investigational Drug Information*, 655

**Group Practice Article**, omission of acknowledgement (letter) 54

**Guynn, James B., Jr.** (author) letter concerning editorial on clinical pharmacy practice, 328

**H**

**Half-Life**, of flucytosine, 180

**Haloperidol**, dyskinesia (ab) 163; limb malformations (ab) 164; lithium carbonate, irreversible brain damage (ab) 58

**Halothane**, postoperative effect on liver enzymes (ab) 392; SGOT level increase (ab) 464

**Hansten, Philip D.** (ed) *Adverse Drug Reactions - Do We Really Know?*, 321

**Hartshorn, Edward A.** (author) *The Antipsychotic Drugs Comprehension Quiz*, 550; book review, 572; *Interactions of CNS Drugs: Psychotherapeutic Agents - The Antianxiety Drugs*, 26; *Interactions of CNS Drugs: Psychotherapeutic Agents - the Antipsychotic Drugs*, 536

**Hays, Dennis F.** (author) letter concerning evaluation of bioavailability, 55

**Health Care Sociology**, 156, 222, 622

**Hemophilia**, influence, 242

**Hendeler, Leslie** (ed) *Wandering from Bed to Bed*, 270; (author) letter concerning five-year Pharm.D., 619

**Hendeler, Leslie** (ed) *Wandering from Bed to Bed*, 270; (author) letter concerning five-year Pharm.D., 619

**Henderson, H. Richard** (co-author) *Pharmacy Involvement - Polydrug Detoxification Unit*, 638

**Heparin**, activity, reduction by gentamicin (letters) 568; bleeding complications, 560; fibrinogen survival in cirrhosis (ab) 579; gentamicin, peritoneal dialysis solutions (letter) 388; interaction with aspirin (ab) 162; thrombocytopenia (ab) 333; variable strengths (letter) 387

**Hepatic Drug-Metabolizing Enzymes**, interaction with phenobarbital (ab) 623

**Heroin**, withdrawal in neonates (ab) 528

**Hexachlorophene**, neurotoxicity (ab) 332

**Hiranaka, Paul K.** (co-author) *Investigational Drug Information*, 655

**Hirschman, Joseph L.** (co-author) PSRO - Participation Pathways for Pharmacists, 553

**Horn, John R.** (author) book review, 461; (co-author) *The Pharmacokinetics of Flucytosine in Cryptococcal Meningitis*, 180

**Hospital Formulary**, revision, 596

**Hospital Prescription Blanks**, use of (letter) 54

**Hospital Rounds**, pharmacist's role (ed) 270

**Hu, Ada Chung Wai** (author) book review, 574

**Hurley, Stephen C.** (co-author) Activities of the Clinical Pharmacist Practicing in the Office of a Family Practitioner, 129

**Hydantoin**, adverse reaction (ab) 669

**Hydrocortisone**, anaphylactic reaction (ab) 331

**Hydroxyzine**, interaction with theophylline (ab) 527

**Hyperbaric Oxygen**, interaction with drugs (letter) 276

**Hypertension**, monitoring, 420

**I**

**Ibuprofen**, evaluation, 501; rheumatoid arthritis (ab) 395

**Ignoffo, Robert J.** (author) Incidence of Bleeding Complications in Patients on Intermittent IV Heparin Therapy, 560

**Imhoff, Thomas E.** (author) book review, 461

**Inderal**, adverse reaction (letter) 455

**Infections**, bacterioides, metronidazole in (ab) 279

**Inovar®**, cardiovascular effects of (ab) 217

**Instructions to Authors**, 47

**Insulin**, adsorption in protein solutions (letter) 664; role in metabolism, 135

**Intestinal Amebiasis** (letter) 569

**Intoxication**, aspirin, salicylates, 350

**Investigational Drug Information**, D-I-T, 655; Lipexal, 656; Threo-dihydroxyphenylserine, 655

**Iodide**, intoxication (ab) 113

**Iodine**, goiter (ab) 112

**Ipecac**, in hydrocarbon ingestion (ab) 164

**Iron**, intoxication (ab) 112

**Isoproterenol**, metabolism in children (ab) 59

**IV** **Therapy**, filtration, 76; guidelines for compatibility (letter) 155; parenteral hyperalimentation, 493

**J**

**Jackson, Eric A.** (author) abstracts, 115

**Jacobs, Richard S.** (author) *Drug Evaluation Data - Calcitonin-Salmon*, 557

**Jeffrey, Louis P.** (author) *Impact of the Pharmacy Technician Upon Pharmacy Service in the Year 2000*, 430

**Jelliffe's Computer Program**, patient monitoring (letter) 516

**Johnson, Curtis** (co-author) *A Self-instructional Learning Package About Parenteral Hyperalimentation for Students of Nursing, Pharmacy and Medicine*, 493

**Johnston, Timothy S.** (author) letter concerning intestinal amebiasis, 569

**Jones, Mark** (author) abstracts, 115, 163, 164, 277, 333, 393, 466

**Juhl, Randy P.** (co-author) letter about family practitioner - group practice article, 54

**Jusko, William J.** (author) letter concerning variable heparin strengths, 387

**K**

**Kanamycin**, dose regimen of (ab) 394

**Kato, Donald B.** (co-author) *Phenformin Induced Lactic Acidosis: A Case Report and Review of the Literature*, 236; (author) letter concerning diphenhydantoin dosage, 274

**Kayser, Steve** (co-editor) *The DIAS Rounds*, 190

**Ketamine Anesthesia**, interaction with amantadine (ab) 213

**Ketoacidosis**, therapy of diabetic-induced, 135

**Kimble, Mary Ann** (author) *The Sleeping Women*, 153

**Klainer, Albert S.** (co-author) *Antineoplastic Agents as a Cause of Fever*, 126

**Knowles, Jimmy H.** (author) abstracts, 113, 114, 115, 333, 392, 393, 394, 395

**Kotabe, Sharonie E.** (co-author) letter giving guidelines for IV compatibility, 155

**Koup, Jeffrey R.** (co-author) letter concerning use of heparin and gentamicin, 338, 568; letter concerning variable heparin strengths, 387

**Kreider, Lloyd A.** (author) letter commenting on prescription renewal article, 666

**Kresel, James J.** (author) letter commenting on tartrazine article, 330

**L**

**Laboratory Tests**, drug interactions, 26, 536

**Lactic Acidosis**, phenformin-induced, 236

**Lamy, Peter P.** (author) *Possible Determinants of the Practice of Pharmacy in the Year 2000*, 426; (co-author) *Technical and Theoretical Aspects of Patient Counseling Using Audiovisual Aids*, 485

**Lauper, R. David** (co-editor) *Drug Evaluation Data*, 42

**Laventurier, Marc** (co-author) *PSRO - Participation Pathways for Pharmacists*, 553

**Law**, and clinical pharmacy, 124; prescription renewals, 489; temporary state licensure for pharmacy residents (ed) 97

**Letters to the Editor**

- AIHP, pharmacy bicentennial speakers, 570
- antacids, for decubitus ulcers, 54
- antibiotic utilization, 155
- ASHP, new goals for, 101
- bacterial meningitis, 457; author's response, 457
- benzyl alcohol, toxicity of, 154
- bioavailability, evaluating, 55
- clinical pharmacist group practice article, omission of acknowledgement, 54
- clinical/pharmacology-pharmacy seminar, 276
- clinics/pharmacy, dilemma of, 54; possible solution to, 55; vs. traditional practice, 329, 568
- chloroquine, intestinal amebiasis, 569
- community pharmacist, vital professional, 618
- community pharmacy practice in the year 2000, 621

**computers**, patient monitoring, 516

**cost effectiveness comparisons**, 517; author's reply, 518

**darvon**, positive results for methadone screening, 515

**debut**, ulcers, antacids for, 54

**degrees**, B.S. and Pharm.D., 569; professional, and deans, 330, 515; vs. self-education, 100

**DCIP** and community practitioners, 207

**digoxin**, error in December 1974 article, 154; error in peptic ulcer case study, 274

**Diodoquin®**, intestinal amebiasis, 569

**diphenhydantoin dosage**, 274

**dopamine** for shock therapy, 456, 665

**drugs** and hyperbaric oxygen, 276

**education**, continuing, 276; list of Pharm.D. programs, 207; open university in Tennessee, 101

**emetine**, intestinal amebiasis, 569

**family practitioner article**, omission of acknowledgement, 54

**five-year Pharm.D.**, 619; editor's response, 620

**gentamicin**, overdosage, 618; reduction in heparin activity, 568

**glue**, fast-drying, hazards of, 515

**heparin**, gentamicin, in peritoneal dialysis solutions, 388; reduction in activity by gentamicin, 568; variable strengths, 387

**hospital prescription blanks**, use of, 54

**humorous poem about Paul de Haen's cards**, 567; de Haen replies, 664

**hyperbaric oxygen**, interaction with drugs, 276

**inaderal**, adverse reaction, 455

**insulin**, adsorption in protein solutions, 664

**intestinal amebiasis**, 569

**IV compatibility**, guidelines for, 155

**Jelliffe's computer program**, patient monitoring, 516

**lidocaine** in myocardial infarction, 275

**meningitis**, bacterial, 457

**my son**, the clinical pharmacist, 457

**open university** in Tennessee, 101

**patient information**, 665

**patient oriented pharmacy practice**, 328; author's response, 329

**peptic ulcer case study**, 386; author's response, 387

**pharmacy**, manuals, 54; quest for professional direction, 206; in the Soviet Union, 154; temporary licensure for residents, 274; women's roles, 516

**polyvinyl chloride plastics**, IV use, 518

**practical drug therapy** '75, continuing education course, 276

**prescription blanks**, use of, 54

**prescription renewals**, reader comment and author response, 666-668

**professional degrees**, and deans, 330, 515; vs. self-education, 100

**residents**, pharmacy, temporary state licensure, 274

**self-education** vs. professional degrees, 100

**tartrazine article**, additional information, 568; author's addendum, 330; praise for, 330

**tetracycline**, intestinal amebiasis, 569

**Levodopa**, interaction with papaverine (ab) 214

**Lewis, Marlane C. Gainor** (co-author) *The Use of Computers in Pharmacy in the Year 2000*, 439

**Licensure**, temporary, for pharmacy residents (ed) 97; (letter) 275

**Lidocaine** (ab) 215; in myocardial infarction (letter) 275

**Lipexal**, investigational drug information, 656

**Literature**, 102, 210, 389, 460, 522, 572; adverse drug reactions, 190; professional, and the pharmacist (ed) 513

**Lithium**, 536; flu-like syndrome (ab) 332; heart failure (ab) 163; multifocal myoclonus (ab) 332; therapy, 17

**Lithium Carbonate**, haloperidol, irreversible brain damage (ab) 58

**Lithocholates**, metabolism (ab) 871

**Lomotil®**, overdose (ab) 114

**Logett, Larry T.** (author) letter concerning drugs and hyperbaric oxygen, 276

**Lukasiewicz, Ronald** (author) letter concerning hazards of fast-drying glues, 515

**Lunen, Hugh N.** (ed) *Drug-Drug Interactions*, 289; *New Developments in Pharmacy - How Does the Institution Meet This Need?*, 453

**Lupus-like Syndrome**, drug induced (ab) 278

**M**

**McCarron, Margaret M.** (author) *An Approach to Clinical Pharmacy*, 12; *A System of Inpatient Drug Monitoring*, 80; *Management of Severe Diabetic Ketoacidosis*, 135

**McCart, Gary** (co-editor) *The DIAS Rounds*, 190

**McClain, P. R.** (co-author) *Isolation, Propagation, Freeze Preservation and Studies of Drug*

Sensitivity of *Toxoplasma gondii* in Human Tissue Culture, 264  
 McCoy, Linda K. (author) abstracts, 392, 464, 465  
 McEvilla, Joseph D. (co-author) The Use of Computers in Pharmacy in the Year 2000, 439  
 McErcher, Patrick L. (author) letter concerning continuing education course, 276  
 McLeod, Don C. (author) Pharmacy Practice in the Year 2000, 406; Structuring Clinical Pharmacy Residencies to Provide Future Patients Drug Therapy Needs, 806; (ed) The Dilemma in Pharmacy Residency Training, 382; Drug Evaluation Data, 42, 361, 501, 577; Strategy for Clinical Pharmacy in Hard Times, 204  
 McMahon, F. Gilbert (author) letter praising "My Son, the Clinical Pharmacist," 457

**M**

Mandrax Overdose, peripheral neuropathy (ab) 577  
 Manzani, Ronald (author) letter on Jelliffe's computer program, patient monitoring, 516  
 Marek, Donald (author) letter concerning dopamine for shock therapy, 458  
 Marketing Rating of Drugs, 144  
 Martin, L. Robert (author) letter about family practitioner - group practice article, 54  
 Medication Instructions, patient compliance (ed) 268  
 Medical Staff, and formulary revision, 596  
 Melphalan, comparison in myeloma (ab) 216; myelomonocytic leukemia (ab) 214  
 Meningitis, bacterial, case study, 242, comment and author response (letters) 457; cryptococcal, flucytosine, 180  
 Meprobamate, death (ab) 393; interactions, 26; malformations (ab) 393  
 Mesoridazine, absorption and excretion (ab) 280  
 Methadone, results of births to patients on (ab) 216; withdrawal, fetal stress (ab) 465; withdrawal in neonates (ab) 528  
 Methadone Hydrochloride, withdrawal symptoms (ab) 214  
 Methaqualone, overdose, peripheral neuropathy (ab) 577  
 Methotrexate, distribution in cerebrospinal fluid (ab) 578  
 Methyldopa, hemolytic anemia (ab) 277; interaction with thiazide (ab) 577; metabolism (ab) 114  
 Methylprednisolone, anaphylactic reaction (ab) 331  
 Metronidazole, bacterioides infections (ab) 279; intestinal amebiasis (letter) 569  
 Michoek, Robert J. (author) letter concerning peptic ulcer case study, 386  
 Miconazole, for coccidioidomycosis (ab) 59  
 Miller, Richard Y. (author) letter concerning hospital prescription blanks, 54  
 Miller, William A. (author) book review, 460  
 Minoxidil, interaction with propranolol (ab) 162; pharmacodynamics of (ab) 578  
 Mitchell, John F. (author) letter concerning the hazards of fast-drying glues, 513  
 Morphine, interaction with gallamine (ab) 277; with pancuronium (ab) 277; with propranolol (ab) 277  
 Morris, Raymond W. (co-author) Technical and Theoretical Aspects of Patient Counseling Using Audiovisual Aids, 485  
 Motrin, evaluation, 501  
 Mrtek, Robert G. (author) letter concerning AIHP, pharmacy bicentennial speakers, 570  
 Mussalam, N. A. (co-author) Isolation, Propagation, Freeze Preservation and Studies of Drug Sensitivity of *Toxoplasma gondii* in Human Tissue Culture, 264  
 Nutrition, parenteral, in pediatrics (ab) 625

**N**

Naloxone, in methadone poisoning (ab) 529  
 Neisseria Meningitidis, case study, 242  
 Nelson, Arthur A., Jr. (co-author) An Evaluation of the Quality of Pharmaceutical Care: A Study of the Pharmacist's Compounding Behavior, 591  
 New Drugs 1973/1974, 504  
 New Drugs, time of marketing, 144; 504  
 New Products Parade, 504  
 Nipride, See Sodium Nitroprusside  
 Nitrofurantoin, hepatic injury (ab) 278  
 Nitroprusside, Sodium, evaluation, 361  
 Nitrous Oxide, interaction with gallamine (ab) 277; with pancuronium (ab) 277  
 Nona, Daniel A. (author) list of Pharm.D. programs (letter) 207  
 Nortriptyline, interaction with alcohol (ab) 527  
 Norwood, G. Joseph (author) Impact of a Clinical Pharmacist's Emphasis on Patient Communication on the Patient's Attitude Toward Pharmacy, 601  
 Novobiocin-Tetracycline, pseudomembranous colitis (ab) 278  
 Nurses, interdisciplinary practice, 420; education, 80; roles, 648

Nurse Practitioner, management of patients with diabetes mellitus (ab) 222  
 Nursing Homes, prescribing in, 365

**O**

Oral Contraceptives, breast cancer (ab) 464; death from myocardial infarction (ab) 528; effects on plasma vitamins, cholesterol and triglycerides (ab) 670; intracranial venous thrombosis (ab) 163; myocardial infarction (ab) 527; stroke (ab) 393  
 Orphenadrine, interaction with chlorpromazine (ab) 623  
 Oxygen Anesthesia, interaction with gallamine (ab) 277, with pancuronium (ab) 277  
 Oxymetholone, perturbations of menstrual cycle by (ab) 217

**P**

Pain, operant conditioning program, 68  
 Pancuronium, interaction with morphine (ab) 277, with nitrous oxide (ab) 277, with oxygen anesthesia (ab) 277, with tubocurarine (ab) 277  
 Papaverine, interaction with levodopa (ab) 214  
 Parenteral Hyperalimentation, 493; in pediatrics (ab) 625  
 Patents, 504  
 Patient, attitude toward pharmacy, 601; compliance (ed) 288; conditioning against chronic pain, 68; counseling, 480, 485; drug therapy needs, 606; education, 601; information (letter) 685; medication history, 80; oriented pharmacy practice (ed) 151, (letter) 328; author response, 329  
 Pediatric Case Studies, Bacterial Meningitis, 242; Pneumocystis Carinii Pneumonia, 657  
 Peptic Ulcer, case study, 86  
 Pellegrino, Edmund D. (author) Meddlesome Medicine and Rational Therapeutics, 480  
 D-Penicillamine, Goodpasture's Syndrome (ab) 464  
 Penicillin, hemolytic anemia (ab) 277, 577; pseudomembranous colitis (ab) 278  
 Pentamidine, in pneumocystis carinii pneumonia, 657  
 Pentazocine, comparison with floctafenine (ab) 529  
 Peptic Ulcer, case study, 86; letter of comment, 386; author response, 387  
 Perry, Paul J. (co-author) Activities of the Clinical Pharmacist Practicing in the Office of a Family Practitioner, 129; letter about family practitioner - group practice article, 54  
 Personnel Placement, 171, 227, 282, 339, 468, 530, 531, 575, 576, 626, 627, 628, 672, 673  
 Pharmaceutical Care, evaluation of quality of, 591  
 Pharmacogenetics, new research (ab) 279  
 Pharmacokinetics, 501; data needed in diseased individuals (ed) 270; drug interactions, 536; drug interactions, antianxiety drugs, 26; flucytosine, 180; ibuprofen, 501; lithium, 17; See also Biopharmaceutics  
 Pharmacy  
 manuals, data for (letter) 54  
 nursing, interdisciplinary practice, 426  
 practice, 480; community (ed) 514; in year 2000 (ed) 454; new developments in (ed) 453; private practitioner (ed) 512; quality of, 591; responsibility of (ed) 383  
 professional standards review, 292, 553  
 quest for professional direction (ed) 45, (letter) 206  
 residents, temporary state licensure (ed) 97, (letter) 275; training, 606, (ed) 382  
 roles, drug advisor to patients (ab) 159; in formulary revision, 596; future, 426  
 service, 553; patient education (ed) 322; who needs it? (ed) 323  
 Soviet Union, impressions of (letter) 154  
 supportive personnel, 434; education and utilization (ed) 452; future roles, 430; future use, 406  
 women in (ed) 663  
 Pharmacy & Therapeutics Committee, formulary revision, 596  
 Pharm.D. Programs, five-year (ed) 384, letter, 619, editorial response, 620; guidelines for (ed) 617; list of (letter) 207  
 Phenacetin, renal disease (ab) 331  
 Phenformin, induced lactic acidosis, 236; and vitamin B<sub>12</sub> deficiency (ab) 162  
 Phenobarbital, interaction with chlorpromazine (ab) 623; with hepatic drug metabolizing enzymes (ab) 623; with vitamin D (ab) 670  
 Phenothiazines and benztropine, fatal paralytic ileus (ab) 465; interactions, 536  
 L-Phenylalanine Mustard, in breast cancer (ab) 280  
 Phenytoin, kinetics and protein binding (ab) 578  
 Phlebitis, 76  
 Physicians, and clinical pharmacy, 129; education, 80; orders, evaluation, 80; role in formulary revision, 596  
 Pickard, Ann S. (co-author) The Effect of In-

Line Final Filtration on Occurrence of Phlebitis, 76  
 Pierpoli, Paul G. (ed) The Rise and Fall of Clinical Pharmacy Education, 97  
 Pietrusko, Robert G. (ed) Clinical Pharmacy Service - Who Needs It?, 323  
 Placebo, interaction with alcohol (ab) 527  
 Plubar, Robert E. (author) book review, 103  
 Pneumocystis Carinii Pneumonia, pediatric case report, 657

Pneumonia, treated with pentamidine, 657  
 Poem, humorous, about Paul de Haen's cards (letters) 567, 664

Poisoning, by salicylates, 350

Polyvinyl Chloride Plastics, IV use (letter) 518

Popovich, Nicholas G. (co-author) Potential Drug Interactions - Fact or Fallacy?, 586

Population, fertility control (ab) 222; growth, 36; and the quality of life (ed) 46

Porter, L. Kent (ed) The Literature and the Pharmacist, 513

Porter, R. Stephen (co-author) letter giving possible solution to dilemma of clinical pharmacy

Potassium Citrate, interaction with calcium gluconate (ab) 466

Potassium Iodide, cardiac irritability (ab) 113

Practolol, effects on plasma-lipids (ab) 279

Pregnancy, *Toxoplasma gondii*, 264

Prescription of drugs, 365; sociology of (ab) 156; rational, 480

Prescription, blanks, hospital (letter) 54; generic and brand name costs (ab) 222; ingredient costs (ab) 158; renewals, legal aspects, 489; comment on article and author response (letters) 666-668

Prince, Randall A. (co-author) Antineoplastic Agents as a Cause of Fever, 126; (ed) The Need for Pharmacokinetic Data in Diseased Individuals, 270

Professional Degrees and Deans (ed) 205, (letters) 330, 515

Professional Organizations, future roles, 426

Professional Standards Review, 292; participation pathways for pharmacists, 553

Progestogen, injectable long-acting contraception (ab) 333

Propoxyphene, overdose (ab) 113

Propranolol, interaction with minoxidil (ab) 162; interaction with morphine (ab) 277; intractable arrhythmias controlled by (ab) 394; kinetics in renal disease (ab) 59; treatment of thyrotoxicosis (ab) 215; treatment of hypertension (ab) 335

Propylthiouracil, liver disease (ab) 215

Prostaglandin E, bronchodilatation (ab) 529; intrauterine death treated with (ab) 334

Prostaglandin F<sub>2</sub> Alpha, bronchoconstriction (ab) 529; pregnancy termination (ab) 331

Pseudoeophedrine, interaction with triprolidine (ab) 213

Psychotherapeutic Drug Interactions, antianxiety drugs, 26; antipsychotic drugs, 536

**Q**

Quality of Pharmacy Practice, 591

Quinidine, hemolytic anemia (ab) 277

Quiz, antipsychotic drugs, 536; parenteral hyperalimentation, 493

**R**

Raleigh, Fred (author) letter concerning adverse reaction to Inderal, 455

Rapp, Robert P. (co-author) A Self-instructional Learning Package About Parenteral Hyperalimentation for Students of Nursing, Pharmacy and Medicine, 493; (ed) Patient Oriented Pharmacy Practice - Does It Include Traditional Services?, 151; letter responding to comments on editorial, 329

Referees for 1975, 674

Rehder, Terry L. (author) abstracts, 165, 214, 215; book review, 523

Reinders, Thomas P. (ed) Patient Education - A Clinical Pharmacy Service, 322

Reinhart, James L. (author) letter concerning bacterial meningitis article, 457

Renal Failure, cefazolin kinetics (ab) 670; reaction to sulfamethoxazole, 660

Research, clinical (ed) 324; compounding accuracy, 591; in drug abuse, 370; new drugs, 504

Residents, Pharmacy, temporary state licensure (ed) 97, (letter) 275; training, 606; (ed) 382

Rifampin, interaction with warfarin (ab) 466

Ribayo, Juan Rodriguez (author) letter commenting on editorial, 330

Robertson, Joel C. (co-author) letter giving possible solution to dilemma of clinical pharmacy, 55

Roffman, David S. (author) letter on peptic ulcer case study, 386

Role Models, scarcity for clinical pharmacists, 12

Romankiewicz, John A. (ed) Spanning the Gap - Clinical Research, 324

Rounds, hospital, pharmacist's role (ed) 270

Rucker, T. Donald (author) PSRO: Current Issues - Future Trends, 292  
Rupp, Claudia A. (co-author) letter giving guidelines for IV compatibility, 155

## S

Salicylates, intoxication, 350; kinetics of in children (ab) 333; percutaneous absorption (ab) 624; See also Aspirin

Schneiweiss, Fred (author) letter on clinical vs. traditional pharmacy practice, 329

Schooff, Kenneth C. (co-author) Pharmacy Involvement - Polydrug Detoxification Unit, 638

Schwartz, Michael A. (author) Educational Needs for Pharmacy Practice in the Year 2000, 447; letter concerning B.S. and Pharm.D. degrees, 569

Seary, Donald M. (co-author) The Effect of In-Line Final Filtration on Occurrence of Phlebitis, 78

Self, Timothy H. (co-author) Acute Renal Failure in a Multisystem Allergic Reaction to Sulfamethoxazole, 660

Self-Education, vs. professional degrees (letter) 100

Self-Instruction, parenteral hyperalimentation, 493

Serum Levels, digoxin (letter) 274; monitoring, lithium therapy, 17

Shearer, Cameron A. (author) abstracts, 185, 213, 215, 216, 217, 278, 332, 333, 334, 465, 528, 529,

Shimomura, Sam K. (co-author) Adverse Drug Reactions, 190; (co-editor) The DIAS Rounds, 190

Siler, W. A. (author) letter concerning self-education, 100

Silkaitis, Raymond P. (author) letter on pharmacy in the Soviet Union, 154

Silver Sulfadiazine, evaluation of (ab) 59

Singletary, James R., Jr. (author) book review, 104

Sitzler, Lynne (co-author) The Impact of the Pharmacy Technologist Upon Pharmacy Practice in the Year 2000, 434

Slining, Judith M. (author) Women's Role in Pharmacy Practice in the Year 2000, 415

Smith, Dorothy L. (ed) Why Should Patients Comply With Medication Instructions?, 268

Sociology, of prescribing (ab) 156

Sodium Cromoglycate, in PGF<sub>2</sub>-induced bronchoconstriction (ab) 529

Sodium Nitroprusside, evaluation data, 361

Sodium Warfarin, ecchymosis (ab) 392; See also Warfarin

Solutions, filtration, 76

Spironolactone, interaction in urinary acidification (ab) 57

Standards, professional review, 292, 553

State Licensure, temporary, for pharmacy residents (ed) 97, (letter) 275

Steiner, Gilbert A. (co-author) Pharmacy Involvement - Polydrug Detoxification Unit, 638

Steroids, peliosis hepatitis (ab) 114

Stewart, Ronald B. (ed) The Fatal Drug-Reaction Debate, 382; What the Pharmacist Needs to Know, 664

St. Onge, George D. (author) letter concerning DICP and community practitioners, 207

Students, women, 412

Stulberg, Cyril (co-author) Isolation, Propagation, Freeze Preservation and Studies of Drug Sensitivity of *Toxoplasma gondii* in Human Tissue Culture, 264

Succinylcholine, hyperventilation (ab) 214

Sulfadiazine, silver, evaluation of (ab) 59

Sulfamethoxazole, adverse reaction, 660

Sulfaphenazole, interaction with cyclophosphamide (ab) 624

Sulfonamides, adverse effects, 190

Sulphisoxazole, and chronic granulomatous disease (ab) 395

Summerfield, Marc R. (author) book review, 389

Supportive Personnel, See Pharmacy Supportive Personnel

Swanson, Larry N. (co-author) Pharmacy Involvement - Polydrug Detoxification Unit, 638

Swift, Robert G., Jr. (co-author) The Effect of In-Line Final Filtration on Occurrence of Phlebitis, 76

## T

Tannic acid, hepatotoxicity (ab) 115

Tartrazine containing drug products, 198, (letters) 330, 568

Technicians, in the year 2000, 430; See also Pharmacy Supportive Personnel

Technologist, pharmacy, 434; See also Pharmacy Supportive Personnel

Temple, Thomas R. (co-author) An Evaluation of the Quality of Pharmaceutical Care: A Study of the Pharmacist's Compounding Behavior, 591

Tests, on antipsychotic drugs, 536; on parenteral hyperalimentation, 493

Tetracycline, intestinal amebiasis (letter) 569

Theophylline, interaction with ephedrine (ab) 527, with hydroxyzine (ab) 527

Thiazide, interaction with methyldopa (ab) 577; pancreatitis, 190

Thioridazine, absorption and excretion (ab) 280; alternative to diazepam (ab) 335; interaction with alcohol (ab) 623, with chlordiazepoxide (ab) 623, with diazepam (ab) 623

Thiethixene, hyponatremia (ab) 279

Thompson, Gregory A. (author) Peptic Ulcer, 86; letter correcting typographical error in article, 274; letter responding to comments on article, 386

Three-dihydroxyphenylserine, investigational drug, 655

Thymoxamine, in PGF<sub>2</sub>-induced bronchoconstriction (ab) 529

Tobias, Dianne E. (ed) Round and Round, 321; letter about peptic ulcer case study, 386

Tolbutamide, inotropic effects (ab) 214

Tortorici, Michael P. (author) letter about darvon and methadone screening, 515

Tourville, John (author) Sodium Nitroprusside Evaluation, 361

Toxoplasma gondii, drug sensitivity, 264

Toxoplasmosis, drug sensitivity, 264

Traffic Accidents, and drugs, 370

Tranquillizers, plasma, effect of oral contraceptives (ab) 670

Trimethadione, adverse reaction (ab) 669

Trimethoprim, interaction with pseudoephedrine (ab) 213

Tso, Teddi C. S. (author) abstracts, 57, 113, 115, 162, 163, 331

Tubocurarine, interaction with gallamine (ab) 277, with pancuronium (ab) 277

## U

Urinary Acidification, effect of spironolactone (ab) 57

## V

Vance, John W. (author) letter concerning variable heparin strengths, 387

Varano, Carmine Raymond (author) letters: concerning women's roles in pharmacy, 516; temporary licensure for pharmacy residents, 274; patient information, 655

Viloxazine Hydrochloride, blood level studies (ab) 625

Vincristine, increased secretion of ADH (ab) 394

Vinyl-chloride, liver disease (ab) 278

Vitamin B<sub>12</sub>, malabsorption with phenobarbital (ab) 670

Vitamin E, coagulopathy (ab) 58

Vitamins, and oral contraceptives (ab) 216; plasma, effect of oral contraceptives (ab) 670

## W

Warfarin, hemorrhage-breast necrosis (ab) 392; interaction with ethacrynic acid (ab) 213, with rifampin (ab) 466; sodium, ecchymosis (ab) 392

Watanabe, Arthur S. (co-author) Adverse Drug Reactions, 190

Weber, Charles E. (author) letter praising editorial, 621

Weinstein, William M. (author) letter concerning term "doctor of pharmacy," 618

Weisburst, Mark (co-author) Acute Renal Failure in a Multisystem Allergic Reaction to Sulfamethoxazole, 660

Wells, Peter G. (author) letter about patient oriented pharmacy practice editorial, 328

Wentz, Margaret R. (author) letter requesting data for pharmacy manuals, 54

West, Sheila (author) Women in Pharmacy - Some Predictions for Women Students and Faculty, 412

White, Eugene V. (author) Prescription Reversals - The Pharmacist's Dilemma, 489; letter responding to comments on article, 667

Whitney, Harvey A. K., Jr. (ed) Educating the Public about Drugs, 571; The Education and Utilization of Pharmacy Supportive Personnel, 452; The Five-Year Pharm.D., 384; (co-author) The Impact of the Pharmacy Technologist Upon Pharmacy Practice in the Year 2000, 434; (author) book review, 103

WHO Expert Committee on Drug Dependence, 249, 300, 370

Winship, Henry W., III (co-author) A Cost Effectiveness Comparison of a Pharmacist Using Three Methods for Identifying Possible Drug Related Problems, 257

Women in Pharmacy, 153; future roles, 412; as practitioners in 2000, 415; roles (letter) 516; salute to (ed) 663

Wood, George C. (co-author) A Cost Effectiveness Comparison of a Pharmacist Using

Three Methods for Identifying Possible Drug Related Problems, 257

World Health Organization Report, Drug Dependence, Part I, 249; Part II, 300; Part III, 370

World Population Conference, 36

## X-Y-Z

Zilz, David (author) Total Medical Staff Participation in Formulary Revision, 596

## ADVERTISERS

Abbott Laboratories

Abbo-Pac® Unit Dose, Ja-8-9, F-66-67

ADIS Press, D-628

American Institute of the History of Pharmacy

Membership Information, F-63, S-473

American Society of Hospital Pharmacists

Drugs in Health Care, S-471, D-636; International Pharmaceutical Abstracts, Ma-231, S-475, D-637

Paul de Haen, Inc.

Three new indices, Ap-189, Ma-276

Drug Intelligence & Clinical Pharmacy, Inc.

Subscription Information, Ja-Ifc, F-Ifc, Mr-Ifc, Ap-Ifc, Ma-Ifc, Ju-Ifc, Jl-Ifc, Ag-Ifc, S-Ifc, O-Ifc, N-Ifc

Drug Intelligence Publications, Inc.

Books and Tapes available, Ja-48, 49, 52, 53, F-106-109, Mr-166-169, Ap-218-221, Ma-256-257, Ju-312-313, Ag-432-433, S-479, S, O, N-center inserts

Clinical Pharmacy Handbook for Patient Counseling, Ag-459, S-525, N-526, D-628

Fate of Drugs in the Organism, Ja-51, Ap-5pc

Fundamentals of Clinical Pharmacokinetics, Ju-326-327, Jl-390-391, Ag-462-463, S-520-521, D-634-635

Fundamentals of Medications, 2nd ed., Ja-ibc, Mr-119, Ap-179, Ju-ibc, D-634-635

Guide to Drug Information, Ma-235, Ju-325, Ag-405

Handbook of Basic Pharmacokinetics, Ju-338, Ag-433, S-500

Handbook of Clinical Drug Data, Ap-175, Ma-284, Ju-337, Jl-369, Ag-458

Handbook of Drug Interactions, Ma-281

Handbooks of IV Additive Reviews, Ja-7

I.V. Additive Reviews, Ma-241

Index Nominum, Ag-467, S-524

Laboratory Manual of Biopharmaceutics and Pharmacokinetics, F-110, Mr-170, Ap-226

Organic Medicaments and Their Synonyms, Mr-123, Ju-287

Principles of Clinical Pharmacy Illustrated by Clinical Case Studies, Ja-50, F-111, Mr-134, Ma-262, Ju-336

USAN 10, Ja-10-11, F-64-65, Ap-224-225

USAN 1975, D-632-633

Eli Lilly and Co.

Keflex®, Ja-3, F-ibc, Mr-ibc, Ap-obc

Keflin® I.V., Ma-ibc, Ju-ibc, Jl-ibc, Ag-ibc

Kefzol® I.V., S-ibc, O-ibc, N-584, D-ibc

Merrell-National Laboratories

Bentyl®, Ja-0bc, F-0bc, Jl-349, S-472, N-605

Personnel Placement, Mr-171, Ap-227, Ma-282, Ju-339, Ag-468, S-530-531, O-575-576, N-626-627-628, D-656, 672-673

Pharmaco, Inc.

In the Fight Against Phlebitis, Jl-0bc

Larson Filter Pin, O-0bc, N-0bc

Larson Safety Caps and Larson Filter Pin, Ag-0bc, S-0bc

UFO, D-0bc

Rhode Island Hospital and University of Rhode Island

Joint Position available, F-101

Roche Laboratories, Inc.

Hospital Pharmacy Program, Mr-160-161, Ap-208-209

The Roche Hospital Pharmacy Advisory Board, Ju-290-291, Jl-344, Ag-400-401

Vahum®, Mr-120-122, Ap-176-178, Ma-232-234-272-273

Vahum® Quiz, Ja-4-6, Jl-346-347, S-476-478

Vahum Tel-E-Dose, Ag-402-404

Smith Kline & French Laboratories

Preparation, Ag-399, S-474, O-535, N-585

Single Unit Packages, N-583, D-631

E. R. Squibb & Sons, Inc.

When the choice is yours . . . , Mr-0bc, Jl-343

When The Decision is Yours, Ma-0bc

University of California, San Francisco

Clinical Pharmacy Teaching Service Position, F-99, Ag-446

University of Cincinnati

Biopharmaceutics Correspondence Course, S-526

University of Massachusetts Medical Center

Senior Clinical Pharmacist, Ja-60

University of Missouri at Kansas City

Faculty Positions, Clinical Pharmacy and

Drug Information, F-99

University of Southern California

Announcement of residencies, Ja-56

World Population Society

Membership Information, Ja-41

Guild of Hospital Pharmacists, S-532

